好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Functional Connectivity Network Shapes Atrophy Spreading in Parkinson’s Disease
Movement Disorders
P8 - Poster Session 8 (5:30 PM-6:30 PM)
3-020

To decipher the mechanisms of network-based neurodegeneration in Parkinson’s disease (PD) investigating the relationship between functional connectivity (FC) in healthy connectome and grey matter (GM) atrophy accumulation in mild PD patients, and to develop a predictive model for atrophy spreading in PD.

Propagation of progressive neuronal loss in PD may be a

multifactorial process depending on regional vulnerability and cell-to-cell spreading of misfolded

proteins.

86 mild-PD patients performed 3DT1-weighted brain MRI at baseline and

every year for 3 years. Functional brain connectome was estimated using resting-state functional

MRI in 60 controls. At each timepoint, regional GM atrophy was calculated in PD. In patients, the

“disease-exposure” (DE) to pathology of each brain region was defined as a function of FC with all

the connected regions in healthy connectome and the severity of atrophy of the connected regions in

patients. Partial correlations were tested between DE of each GM region at 1-year and 2-year

follow-up and atrophy progression at 2-year and 3-year follow-up. Prediction models of atrophy at

2-year and 3-year follow-up were estimated using stepwise regression models.

In mild PD patients, regional DE at 1-year correlated with atrophy accumulation at 2-year.

Furthermore, DE at 1-year and 2-year was associated with atrophy at 3-year. Models including DE

predict GM atrophy accumulation over 3 years in the caudate nucleus, frontal, parietal and temporal

brain regions.

This study showed that the functional organization of the brain connectome shapes the course of atrophy in the early stages of PD.

 

Supported by. This work was supported by the Ministry of 好色先生, Science, and Technological Development of the Republic of Serbia [grant number #175090] and the Italian Ministry of Health [grant number # RF-2018-12366746].

 

Authors/Disclosures
Edoardo G. Spinelli, MD
PRESENTER
Dr. Spinelli has nothing to disclose.
Silvia Basaia Silvia Basaia has nothing to disclose.
Federica Agosta (San Raffaele Scientific Institute) Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.
Elisabetta Sarasso Elisabetta Sarasso has nothing to disclose.
Roberta Balestrino (Università San Raffaele) No disclosure on file
Tanya Stojkovic Tanya Stojkovic has nothing to disclose.
Iva Stankovic (Neurology Clinic, Clinical Center of Serbia, University of Belgrade) Iva Stankovic has nothing to disclose.
Alexandra Tomic No disclosure on file
Vladana Markovic No disclosure on file
Francesca Vignaroli No disclosure on file
Elka Stefanova No disclosure on file
Vladimir S. Kostic, MD, PhD (Institute of Neurology CCS) Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. An immediate family member of Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alkaloid. The institution of Dr. Kostic has received research support from Ministry of 好色先生, Science and Technological Development of Serbia.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.